Tag Archives: Novartis

Off-Label Whistleblower Suits: Slower and Subtler

Author: Mary Holloway

Although the news of pharmaceutical and medical device settlements in 2010 would lead you to believe otherwise, the rate of new qui tam filings has slowed and the accusations are focused more on subtle versus blatant violations according to an article in the Rx Compliance Report. This is a good sign for an industry that has been working hard trying to revise its marketing practices and eliminate off-label promotion. Continue reading

AdvaMed 2010 Highlights: Changing 510(k)s, Pricing and Healthcare Reform

Originally viewed on BeakerBeat.

To keep up with the best in Good Promotional Practices, subscribe to our GPP RSS feed, our Facebook page, our Twitter stream or our LinkedIn group.